Linagliptin 1a Pharma

Linagliptin, the active ingredient in Linagliptin 1a Pharma, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It is used to improve glycaemic control in adults with type 2 diabetes mellitus, as part of a comprehensive diabetes management plan.

GNH USA supplies Linagliptin 1a Pharma as a licensed, GDP-compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under EU-market standards. The company ensures quality assurance, traceability and regulatory compliance for each batch.

Linagliptin is a DPP-4 inhibitor used in the treatment of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): reduces blood glucose levels when used alone. - Type 2 diabetes mellitus (combination therapy): enhances the effect of other antidiabetic agents such as metformin or insulin. - Type 2 diabetes mellitus with renal impairment: can be used without dose adjustment, supporting patients with reduced kidney function.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Gastrointestinal discomfort: includes nausea, abdominal pain or dyspepsia. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: such as angioedema or anaphylaxis. - Bullous pemphigoid: rare autoimmune skin disorder presenting with blistering lesions.

Linagliptin should be prescribed after evaluating the following considerations. - Renal function assessment: monitor kidney status, especially in patients with chronic kidney disease. - Hepatic impairment monitoring: use caution in patients with liver disease. - Cardiovascular disease: consider risk-benefit in patients with heart failure. - Pregnancy and breastfeeding: safety not established; avoid unless clearly needed. - Concomitant insulin or sulfonylurea therapy: may increase risk of hypoglycaemia. - Store at room temperature: keep in the original pack, protect from moisture.

Linagliptin may interact with other medicines as follows.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate dehydration, especially in the elderly. - NSAIDs: concurrent use may affect renal function. - Insulin or sulfonylureas: combined therapy can raise the likelihood of hypoglycaemia.